BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10697955)

  • 1. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector.
    Ohsugi K; Kobayashi K; Itoh K; Sakuraba H; Sakuragawa N
    J Hum Genet; 2000; 45(1):1-5. PubMed ID: 10697955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
    Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
    Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
    Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
    Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preselective gene therapy for Fabry disease.
    Qin G; Takenaka T; Telsch K; Kelley L; Howard T; Levade T; Deans R; Howard BH; Malech HL; Brady RO; Medin JA
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3428-33. PubMed ID: 11248095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.
    Takahashi H; Hirai Y; Migita M; Seino Y; Fukuda Y; Sakuraba H; Kase R; Kobayashi T; Hashimoto Y; Shimada T
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13777-82. PubMed ID: 12370426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-viral, integrin-mediated gene transfer into fibroblasts from patients with lysosomal storage diseases.
    Estruch EJ; Hart SL; Kinnon C; Winchester BG
    J Gene Med; 2001; 3(5):488-97. PubMed ID: 11601762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
    Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
    J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells.
    Yoshimitsu M; Higuchi K; Ramsubir S; Nonaka T; Rasaiah VI; Siatskas C; Liang SB; Murray GJ; Brady RO; Medin JA
    Gene Ther; 2007 Feb; 14(3):256-65. PubMed ID: 16929352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and characterization of human alpha-galactosidase A expressed in insect cells using a baculovirus vector.
    Chen Y; Jin M; Goodrich L; Smith G; Coppola G; Calhoun DH
    Protein Expr Purif; 2000 Nov; 20(2):228-36. PubMed ID: 11049747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
    Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
    Germain DP
    J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector.
    Medin JA; Tudor M; Simovitch R; Quirk JM; Jacobson S; Murray GJ; Brady RO
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7917-22. PubMed ID: 8755577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.
    Miyamura N; Araki E; Matsuda K; Yoshimura R; Furukawa N; Tsuruzoe K; Shirotani T; Kishikawa H; Yamaguchi K; Shichiri M
    J Clin Invest; 1996 Oct; 98(8):1809-17. PubMed ID: 8878432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.
    Fan JQ; Ishii S; Asano N; Suzuki Y
    Nat Med; 1999 Jan; 5(1):112-5. PubMed ID: 9883849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
    Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.
    Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ
    Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy.
    Sawada K; Mizoguchi K; Hishida A; Kaneko E; Koide Y; Nishimura K; Kimura M
    Clin Nephrol; 1996 May; 45(5):289-94. PubMed ID: 8738659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease.
    Takenaka T; Qin G; Brady RO; Medin JA
    Hum Gene Ther; 1999 Aug; 10(12):1931-9. PubMed ID: 10466627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease.
    Lee CJ; Fan X; Guo X; Medin JA
    J Cardiol; 2011 Jan; 57(1):115-22. PubMed ID: 20846825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Ser-65 in the activity of alpha-galactosidase A: characterization of a point mutation (S65T) detected in a patient with Fabry disease.
    Ishii S; Suzuki Y; Fan JQ
    Arch Biochem Biophys; 2000 May; 377(2):228-33. PubMed ID: 10845698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.